(CercleFinance.com) – Cellectis said Monday that AstraZeneca had finalized its additional investment of $140 million in the company, in accordance with the operation which was announced last November.
The biotechnology company, specializing in immunotherapies, indicates that the completion of the operation follows the approval of the French Ministry of the Economy and the satisfaction of other conditions precedent.
As part of the transaction, AstraZeneca today subscribed for ten million ‘Class A’ preferred shares and 18 million ‘Class B’ shares, in both cases at a unit price of five dollars. by title.
As a result, the pharmaceutical giant now holds 44% of the capital and 30% of the voting rights of Cellectis, which will allow it to obtain two seats on the board of directors with the entry of Marc Dunoyer and Doctor Tyrell Rivers into the board. of the instance.
As part of their collaboration, AstraZeneca intends to rely on Cellectis’ gene editing technologies to design new cellular therapies against cancer.
In detail, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 product candidates could be explored for development.
Following these announcements, Cellectis shares rose by more than 6% on Monday on the Paris Stock Exchange, bringing its gains over the past 12 months to more than 68%.